Our company is a biotechnology company aiming for "a world that can treat ALS".


Company name
Jiksak Bioengineering, Inc.
AIRBIC A24 room, 7-7 Shin-Kawasaki,Saiwai-ku Kawasaki-shi, Kanagawa, 212-0032
Jiro KAWADA, Ph.D, President and CEO


Jiro Kawada,Ph.D. Chief Executive Officer
Jiro Kawada,Ph.D. is a founder of Jiksak Bioengineering. He serves as CEO. He researched about stem cell culture and a microfluidic system for 9 years. To apply the nerve organoid technology to ALS drug discovery, he established Jiksak Bioengineering in 2017. He obtained Ph.D. in engineering from the University of Tokyo.
Keita Shibuya Senior Scientist
Keita Shibuya is currently working as a Senior Scientist. He focuses on development of “Nerve Organoid”.He received Masters of Science from Tokyo University of Science. He was engaged in research on cancer stem cells as a research associate at Yamagata University. Next, he was engaged in research on cancer organoids at a pharmaceutical company.
Norihiro Yumoto, Ph.D. Chief Technology Officer
Ph.D. in Kyoto University in 2008. He had been a researcher at NYU Langone Medical Center for 8 years since 2009. He identified “the retrograde signal, inducing presynaptic differentiation, from skeletal muscle to the motor nerve terminals”, which had been elusive for a long time, and published it in Nature journal in 2012. He worked in medical affairs department in AstraZeneca and joined Jiksak Bioengineering in July 2018. He is leading drug discovery projects focusing on the NMJ in the company.
Shinji Tokunaga,Ph.D. Chief Operating Officer
Shinji Tokunaga,Ph.D. has 6 years combined experience in pharmaceutical industry and academic research. Prior to joining Jiksak Bioengineering he was a scientist of RaQualia Pharma. Before that time, he was a scientist of National Center of Neurology and Psychiatry and led identifying of novel mechanism and therapeutic targets against neurodegenerative diseases. He received his PhD from Waseda University.
Masahiro Samejima Outside Director
Eisaku NakamuraAdvisor
Kubota Pharmaceutical Holdings Co., Ltd. Outside Director etc.
Yoshiho IkeuchiTechnical advisor
Technical Advisor
Kevin EgganTechnical advisor
Professor in the Department of Stem Cell and Regenerative Biology, Harvard University